A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|DRUG: Placebo|DRUG: Nab-paclitaxel|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Filgrastim|DRUG: Pegfilgrastim
Sponsor: Hoffmann-La Roche